RU2005102002A - Новые производные тетрагидропиридина - Google Patents
Новые производные тетрагидропиридина Download PDFInfo
- Publication number
- RU2005102002A RU2005102002A RU2005102002/04A RU2005102002A RU2005102002A RU 2005102002 A RU2005102002 A RU 2005102002A RU 2005102002/04 A RU2005102002/04 A RU 2005102002/04A RU 2005102002 A RU2005102002 A RU 2005102002A RU 2005102002 A RU2005102002 A RU 2005102002A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- tetrahydropyridine
- carboxylic acid
- ethoxy
- amide
- Prior art date
Links
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title 1
- -1 racemates Chemical class 0.000 claims 82
- 239000000203 mixture Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 7
- 206010019280 Heart failures Diseases 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 6
- 230000036454 renin-angiotensin system Effects 0.000 claims 6
- 230000000877 morphologic effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000002249 Diabetes Complications Diseases 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 206010038419 Renal colic Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000005605 benzo group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- FDCDATVCOAKKCS-UHFFFAOYSA-N OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O.ClC1=C(CNC2CC2)C=CC=C1 FDCDATVCOAKKCS-UHFFFAOYSA-N 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 239000000464 adrenergic agent Substances 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- KJYVKUQRRKDPAX-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]cyclopropanamine Chemical compound ClC1=CC=CC(CNC2CC2)=C1Cl KJYVKUQRRKDPAX-UHFFFAOYSA-N 0.000 claims 2
- CRIMYHBFDHWKQY-UHFFFAOYSA-N n-[(2,3-dimethylphenyl)methyl]cyclopropanamine Chemical compound CC1=CC=CC(CNC2CC2)=C1C CRIMYHBFDHWKQY-UHFFFAOYSA-N 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- OLHHRXWVIGFHIL-UHFFFAOYSA-N 4-[4-[2-(2-bromo-5-fluorophenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)F)=C1Br)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F OLHHRXWVIGFHIL-UHFFFAOYSA-N 0.000 claims 1
- JAYUVWYXJOIPAP-UHFFFAOYSA-N 4-[4-[2-(2-bromo-5-fluorophenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound FC1=CC=C(Br)C(OCCOC=2C=CC(=CC=2)C=2CCNCC=2C(=O)N(CC=2C(=C(Cl)C=CC=2)Cl)C2CC2)=C1 JAYUVWYXJOIPAP-UHFFFAOYSA-N 0.000 claims 1
- FIKPVBOZTALOIJ-UHFFFAOYSA-N 4-[4-[2-(2-bromo-5-fluorophenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dimethylphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=CC(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC=C(F)C=3)Br)=CC=2)=C1C FIKPVBOZTALOIJ-UHFFFAOYSA-N 0.000 claims 1
- CZUCEGQMRLRKTB-UHFFFAOYSA-N 4-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine Chemical compound CC(C(C)=C1)=CC(OCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)=C1Cl.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F CZUCEGQMRLRKTB-UHFFFAOYSA-N 0.000 claims 1
- MKDSJHRSXBWOCM-UHFFFAOYSA-N 4-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dimethylphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound C1=C(C)C(C)=CC(Cl)=C1OCCOC1=CC=C(C=2CCNCC=2C(=O)N(CC=2C(=C(C)C=CC=2)C)C2CC2)C=C1 MKDSJHRSXBWOCM-UHFFFAOYSA-N 0.000 claims 1
- PRVXVDMJBASGMZ-UHFFFAOYSA-N 4-[4-[2-(2-chloro-5-fluorophenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound FC1=CC=C(Cl)C(OCCOC=2C=CC(=CC=2)C=2CCNCC=2C(=O)N(CC=2C(=C(Cl)C=CC=2)Cl)C2CC2)=C1 PRVXVDMJBASGMZ-UHFFFAOYSA-N 0.000 claims 1
- GNNWAEGFKWAMAN-UHFFFAOYSA-N 4-[4-[2-(3-chloro-2,6-difluorophenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound FC1=CC=C(Cl)C(F)=C1OCCOC1=CC=C(C=2CCNCC=2C(=O)N(CC=2C(=C(Cl)C=CC=2)Cl)C2CC2)C=C1 GNNWAEGFKWAMAN-UHFFFAOYSA-N 0.000 claims 1
- DETFOAQXXGPHST-UHFFFAOYSA-N 4-[4-[2-(3-chloro-2,6-difluorophenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dimethylphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=CC(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=C(Cl)C=CC=3F)F)=CC=2)=C1C DETFOAQXXGPHST-UHFFFAOYSA-N 0.000 claims 1
- WZOOWBZCJFOLAU-UHFFFAOYSA-N 4-[4-[2-(3-chloro-2,6-difluorophenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2-fluoro-5-methoxyphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound COC1=CC=C(F)C(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=C(Cl)C=CC=3F)F)=CC=2)=C1 WZOOWBZCJFOLAU-UHFFFAOYSA-N 0.000 claims 1
- JMGIEABAFVXNPY-UHFFFAOYSA-N 4-[4-[2-(4-chloro-2-methoxyphenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound COC1=CC(Cl)=CC=C1OCCOC1=CC=C(C=2CCNCC=2C(O)=O)C=C1 JMGIEABAFVXNPY-UHFFFAOYSA-N 0.000 claims 1
- OZEMDWYPAFICGO-UHFFFAOYSA-N 4-[4-[2-(4-chloro-2-methoxyphenoxy)ethoxy]phenyl]-n-cyclopropyl-n-[(2,3-dimethylphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound COC1=CC(Cl)=CC=C1OCCOC1=CC=C(C=2CCNCC=2C(=O)N(CC=2C(=C(C)C=CC=2)C)C2CC2)C=C1 OZEMDWYPAFICGO-UHFFFAOYSA-N 0.000 claims 1
- BJHAITPBNSBYQP-UHFFFAOYSA-N 4-[4-[2-[2-chloro-4-(trifluoromethyl)phenoxy]ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=CC(C(F)(F)F)=C1)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F BJHAITPBNSBYQP-UHFFFAOYSA-N 0.000 claims 1
- OFJPCRUQKSZFFI-UHFFFAOYSA-N 4-[4-[2-[2-chloro-4-(trifluoromethyl)phenoxy]ethoxy]phenyl]-n-cyclopropyl-n-[(2-fluoro-5-methoxyphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound COC1=CC=C(F)C(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC(=CC=3)C(F)(F)F)Cl)=CC=2)=C1 OFJPCRUQKSZFFI-UHFFFAOYSA-N 0.000 claims 1
- PFZAREPYJMRPPQ-UHFFFAOYSA-N 4-[4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound C1CNCC(C(=O)O)=C1C(C=C1)=CC=C1CCCOC1=C(F)C=CC(F)=C1F PFZAREPYJMRPPQ-UHFFFAOYSA-N 0.000 claims 1
- ZKFMOUQSZRSTGS-UHFFFAOYSA-N 4-[4-[3-(2,5-difluorophenoxy)propyl]phenyl]-N-methyl-N-(2-phenylethyl)-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound C=1C=C(CCCOC=2C(=CC=C(F)C=2)F)C=CC=1C=1CCNCC=1C(=O)N(C)CCC1=CC=CC=C1 ZKFMOUQSZRSTGS-UHFFFAOYSA-N 0.000 claims 1
- CKJMNMSAMKXMGW-UHFFFAOYSA-N 4-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound C1CNCC(C(=O)O)=C1C(C=C1)=CC=C1CCCOC1=CC(F)=CC=C1Br CKJMNMSAMKXMGW-UHFFFAOYSA-N 0.000 claims 1
- ZUESJUDDPXQLMZ-UHFFFAOYSA-N 4-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-(2-phenylethyl)-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound FC1=CC=C(Br)C(OCCCC=2C=CC(=CC=2)C=2CCNCC=2C(=O)N(CCC=2C=CC=CC=2)C2CC2)=C1 ZUESJUDDPXQLMZ-UHFFFAOYSA-N 0.000 claims 1
- XQYYULLHWJYZAL-UHFFFAOYSA-N 4-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[2-(2-methylphenyl)ethyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=CC=C1CCN(C(=O)C=1CNCCC=1C=1C=CC(CCCOC=2C(=CC=C(F)C=2)Br)=CC=1)C1CC1 XQYYULLHWJYZAL-UHFFFAOYSA-N 0.000 claims 1
- OUPMEDDKMUSRRH-UHFFFAOYSA-N 4-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-methyl-N-(2-phenylethyl)-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound C=1C=C(CCCOC=2C(=CC=CC=2)Cl)C=CC=1C=1CCNCC=1C(=O)N(C)CCC1=CC=CC=C1 OUPMEDDKMUSRRH-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- UZWCDNSYWBBQFF-UHFFFAOYSA-N CC(C(C)=C1)=CC(OCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)=C1Cl.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound CC(C(C)=C1)=CC(OCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)=C1Cl.BrC1=C(CNC2CC2)C=CC=C1 UZWCDNSYWBBQFF-UHFFFAOYSA-N 0.000 claims 1
- INCNPQBMBHXFKB-UHFFFAOYSA-N CC(C(F)=C1OCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)=CC=C1F.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound CC(C(F)=C1OCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)=CC=C1F.BrC1=C(CNC2CC2)C=CC=C1 INCNPQBMBHXFKB-UHFFFAOYSA-N 0.000 claims 1
- ONZHLAVSPLFYDK-UHFFFAOYSA-N CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.BrC1=C(CNC2CC2)C=CC=C1 ONZHLAVSPLFYDK-UHFFFAOYSA-N 0.000 claims 1
- PDOMPPVVHBAZMN-UHFFFAOYSA-N CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.ClC1=C(CNC2CC2)C=CC=C1 PDOMPPVVHBAZMN-UHFFFAOYSA-N 0.000 claims 1
- BZGDDLVKNMVGEY-UHFFFAOYSA-N CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.ClC1=CC=CC(CNC2CC2)=C1 Chemical compound CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.ClC1=CC=CC(CNC2CC2)=C1 BZGDDLVKNMVGEY-UHFFFAOYSA-N 0.000 claims 1
- WCFHYCYQPQZUPW-UHFFFAOYSA-N CC1=CC=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound CC1=CC=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.ClC1=C(CNC2CC2)C=CC=C1 WCFHYCYQPQZUPW-UHFFFAOYSA-N 0.000 claims 1
- KYGRGPSFZXXEOQ-UHFFFAOYSA-N CCNCC(C=CC=C1)=C1Cl.CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O Chemical compound CCNCC(C=CC=C1)=C1Cl.CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O KYGRGPSFZXXEOQ-UHFFFAOYSA-N 0.000 claims 1
- ZNBPHDCJVIPZGU-UHFFFAOYSA-N CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O Chemical compound CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O ZNBPHDCJVIPZGU-UHFFFAOYSA-N 0.000 claims 1
- CATGJPXXNBWLGY-UHFFFAOYSA-N CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O Chemical compound CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O CATGJPXXNBWLGY-UHFFFAOYSA-N 0.000 claims 1
- HAGPKULQGAISMT-UHFFFAOYSA-N CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1F)=O Chemical compound CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1F)=O HAGPKULQGAISMT-UHFFFAOYSA-N 0.000 claims 1
- ASGJXOLSOIHFOV-UHFFFAOYSA-N CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O Chemical compound CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O ASGJXOLSOIHFOV-UHFFFAOYSA-N 0.000 claims 1
- AHLPFJBQJCOOEM-UHFFFAOYSA-N CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O Chemical compound CCNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O AHLPFJBQJCOOEM-UHFFFAOYSA-N 0.000 claims 1
- RLAJEWNRZVQERT-UHFFFAOYSA-N CN(CCC1=CC=CC=C1)C(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O Chemical compound CN(CCC1=CC=CC=C1)C(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O RLAJEWNRZVQERT-UHFFFAOYSA-N 0.000 claims 1
- IBINYHBPUAFWEM-UHFFFAOYSA-N CNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O Chemical compound CNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O IBINYHBPUAFWEM-UHFFFAOYSA-N 0.000 claims 1
- FFZCAQPMFHQQLV-UHFFFAOYSA-N CNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2F)C=C1)=O Chemical compound CNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2F)C=C1)=O FFZCAQPMFHQQLV-UHFFFAOYSA-N 0.000 claims 1
- XQRFFDCYSPAAIJ-UHFFFAOYSA-N CNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=CC=C2)=C2Cl)C=C1)=O Chemical compound CNCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=CC=C2)=C2Cl)C=C1)=O XQRFFDCYSPAAIJ-UHFFFAOYSA-N 0.000 claims 1
- XKMQROHWMGOQKF-UHFFFAOYSA-N CNCCC(C=CC=C1)=C1Cl.COC1=C(COCCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)C=CC=C1 Chemical compound CNCCC(C=CC=C1)=C1Cl.COC1=C(COCCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)C=CC=C1 XKMQROHWMGOQKF-UHFFFAOYSA-N 0.000 claims 1
- ZVQMMGFSCORCQD-UHFFFAOYSA-N CNCCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O Chemical compound CNCCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2Br)C=C1)=O ZVQMMGFSCORCQD-UHFFFAOYSA-N 0.000 claims 1
- HHGGNVCKSPISQR-UHFFFAOYSA-N CNCCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2F)C=C1)=O Chemical compound CNCCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2F)C=C1)=O HHGGNVCKSPISQR-UHFFFAOYSA-N 0.000 claims 1
- BIOIYFMBFYBLFN-UHFFFAOYSA-N CNCCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=CC=C2)=C2Cl)C=C1)=O Chemical compound CNCCC(C=CC=C1)=C1Cl.OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=CC=C2)=C2Cl)C=C1)=O BIOIYFMBFYBLFN-UHFFFAOYSA-N 0.000 claims 1
- AGXVPERPOTXPOZ-UHFFFAOYSA-N COC(C=C(C=C1)Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F Chemical compound COC(C=C(C=C1)Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F AGXVPERPOTXPOZ-UHFFFAOYSA-N 0.000 claims 1
- NXYRAWGXPDRHKS-UHFFFAOYSA-N COC(C=CC(Cl)=C1)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound COC(C=CC(Cl)=C1)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.BrC1=C(CNC2CC2)C=CC=C1 NXYRAWGXPDRHKS-UHFFFAOYSA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- POJDTOUFXRCBQD-UHFFFAOYSA-N N-[(2-bromophenyl)methyl]cyclopropanamine 4-[4-[2-[2-chloro-4-(trifluoromethyl)phenoxy]ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=CC(C(F)(F)F)=C1)=C1Cl)=O.BrC1=C(CNC2CC2)C=CC=C1 POJDTOUFXRCBQD-UHFFFAOYSA-N 0.000 claims 1
- IUQSTLIRGUEZBZ-UHFFFAOYSA-N N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine 4-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound CC(C=C1Cl)=CC(Cl)=C1OCCOC(C=C1)=CC=C1C(CCNC1)=C1C(O)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F IUQSTLIRGUEZBZ-UHFFFAOYSA-N 0.000 claims 1
- DSGKZLORNLKYGE-UHFFFAOYSA-N N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine 4-[4-[2-(2,6-difluoro-3-methylphenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound CC(C(F)=C1OCCOC(C=C2)=CC=C2C(CCNC2)=C2C(O)=O)=CC=C1F.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F DSGKZLORNLKYGE-UHFFFAOYSA-N 0.000 claims 1
- VGDGIDMFMPUSEC-UHFFFAOYSA-N N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine 4-[4-[2-(2-fluorophenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=CC=C1)=C1F)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F VGDGIDMFMPUSEC-UHFFFAOYSA-N 0.000 claims 1
- SZQLGQZZRDFDNT-UHFFFAOYSA-N N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine 4-[4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxylic acid Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F SZQLGQZZRDFDNT-UHFFFAOYSA-N 0.000 claims 1
- WEUZIYGMGQBWKB-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.BrC1=C(CNC2CC2)C=CC=C1 WEUZIYGMGQBWKB-UHFFFAOYSA-N 0.000 claims 1
- FOPFDYMAVXHJDQ-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 FOPFDYMAVXHJDQ-UHFFFAOYSA-N 0.000 claims 1
- DHXWJLKRNGXRLE-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.ClC1=CC=CC(CNC2CC2)=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.ClC1=CC=CC(CNC2CC2)=C1 DHXWJLKRNGXRLE-UHFFFAOYSA-N 0.000 claims 1
- FHRWOXLRCVVHBI-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC(F)=C1)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F FHRWOXLRCVVHBI-UHFFFAOYSA-N 0.000 claims 1
- YOFPWKYMENYYPS-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC=C1)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(Cl)=CC=C1)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 YOFPWKYMENYYPS-UHFFFAOYSA-N 0.000 claims 1
- LTFYQVQKCUELRA-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O.BrC1=C(CNC2CC2)C=CC=C1 LTFYQVQKCUELRA-UHFFFAOYSA-N 0.000 claims 1
- YLFOBQXEKBNVGE-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O.ClC1=C(CNC2CC2)C=CC=C1 YLFOBQXEKBNVGE-UHFFFAOYSA-N 0.000 claims 1
- JTAJFTLMUBHVPB-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC(F)=C1)=C1F)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F JTAJFTLMUBHVPB-UHFFFAOYSA-N 0.000 claims 1
- VRNCKDSIERGJKS-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1Cl)=C1F)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1Cl)=C1F)=O.BrC1=C(CNC2CC2)C=CC=C1 VRNCKDSIERGJKS-UHFFFAOYSA-N 0.000 claims 1
- IIZFSAAMHHDTKP-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1Cl)=C1F)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1Cl)=C1F)=O.ClC1=C(CNC2CC2)C=CC=C1 IIZFSAAMHHDTKP-UHFFFAOYSA-N 0.000 claims 1
- MMYKJCRKGKRAMJ-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 MMYKJCRKGKRAMJ-UHFFFAOYSA-N 0.000 claims 1
- DUJJZXMAAPTKPU-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1F)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1F)=O.BrC1=C(CNC2CC2)C=CC=C1 DUJJZXMAAPTKPU-UHFFFAOYSA-N 0.000 claims 1
- AUEUSDJOAASXDE-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1F)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C(F)=CC=C1F)=C1F)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F AUEUSDJOAASXDE-UHFFFAOYSA-N 0.000 claims 1
- UAAMNIUIOHBEHR-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C(Cl)=C1)Cl)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C(Cl)=C1)Cl)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 UAAMNIUIOHBEHR-UHFFFAOYSA-N 0.000 claims 1
- FRWRZZMHCRCTDJ-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C(Cl)=C1)Cl)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C(Cl)=C1)Cl)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F FRWRZZMHCRCTDJ-UHFFFAOYSA-N 0.000 claims 1
- UACCJPLQYXGOKY-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)Cl)=C1Cl)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)Cl)=C1Cl)=O.BrC1=C(CNC2CC2)C=CC=C1 UACCJPLQYXGOKY-UHFFFAOYSA-N 0.000 claims 1
- BMUPWLPNGPOYBN-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)Cl)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)Cl)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 BMUPWLPNGPOYBN-UHFFFAOYSA-N 0.000 claims 1
- MSNCATYIARHVEV-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)Cl)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)Cl)=C1Cl)=O.FC(C1=CC=CC(CNC2CC2)=C1Cl)(F)F MSNCATYIARHVEV-UHFFFAOYSA-N 0.000 claims 1
- AGJHSCWCHRUDSR-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)F)=C1Br)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)F)=C1Br)=O.BrC1=C(CNC2CC2)C=CC=C1 AGJHSCWCHRUDSR-UHFFFAOYSA-N 0.000 claims 1
- QFTQGLHOWCIIKA-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)F)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=C(C=C1)F)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 QFTQGLHOWCIIKA-UHFFFAOYSA-N 0.000 claims 1
- YDTJXHYISBJHOU-UHFFFAOYSA-N OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=CC=C1Cl)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C(C=C1)=CC=C1OCCOC(C=CC=C1Cl)=C1Cl)=O.ClC1=C(CNC2CC2)C=CC=C1 YDTJXHYISBJHOU-UHFFFAOYSA-N 0.000 claims 1
- YMEVXRPRIIMOPU-UHFFFAOYSA-N OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.BrC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.BrC1=C(CNC2CC2)C=CC=C1 YMEVXRPRIIMOPU-UHFFFAOYSA-N 0.000 claims 1
- KSKHDVZPUZEIFF-UHFFFAOYSA-N OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.ClC1=CC=CC(CNC2CC2)=C1 Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.ClC1=CC=CC(CNC2CC2)=C1 KSKHDVZPUZEIFF-UHFFFAOYSA-N 0.000 claims 1
- MLVDIXQJPKGCSW-UHFFFAOYSA-N OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.FC1=CC=CC(Cl)=C1CNC1CC1 Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C(F)=CC=C2F)=C2F)C=C1)=O.FC1=CC=CC(Cl)=C1CNC1CC1 MLVDIXQJPKGCSW-UHFFFAOYSA-N 0.000 claims 1
- XDFJUBGZYDVTEA-UHFFFAOYSA-N OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2F)C=C1)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=C(C=C2)F)=C2F)C=C1)=O.ClC1=C(CNC2CC2)C=CC=C1 XDFJUBGZYDVTEA-UHFFFAOYSA-N 0.000 claims 1
- ZVWWIMMQWMMOMY-UHFFFAOYSA-N OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=CC=C2)=C2Cl)C=C1)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound OC(C(CNCC1)=C1C1=CC=C(CCCOC(C=CC=C2)=C2Cl)C=C1)=O.ClC1=C(CNC2CC2)C=CC=C1 ZVWWIMMQWMMOMY-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000000219 Sympatholytic Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012050 conventional carrier Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- GCJYLAWVUWEHLW-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]cyclopropanamine Chemical compound ClC1=CC=CC=C1CNC1CC1 GCJYLAWVUWEHLW-UHFFFAOYSA-N 0.000 claims 1
- BTBDLUOYLCXSMK-UHFFFAOYSA-N n-[(3,5-dimethoxyphenyl)methyl]cyclopropanamine Chemical compound COC1=CC(OC)=CC(CNC2CC2)=C1 BTBDLUOYLCXSMK-UHFFFAOYSA-N 0.000 claims 1
- NJHZDGHFBLATGX-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]cyclopropanamine Chemical compound ClC1=CC=CC=C1CCNC1CC1 NJHZDGHFBLATGX-UHFFFAOYSA-N 0.000 claims 1
- CEQDKNLDFWAMEL-UHFFFAOYSA-N n-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]cyclopropanamine Chemical compound FC(F)(F)C1=CC=CC(CNC2CC2)=C1Cl CEQDKNLDFWAMEL-UHFFFAOYSA-N 0.000 claims 1
- CSZTZLUZEKYHIN-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-fluorophenoxy)ethoxy]phenyl]-n-[(2,3-dimethylphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=CC(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC(F)=CC=3Cl)Cl)=CC=2)=C1C CSZTZLUZEKYHIN-UHFFFAOYSA-N 0.000 claims 1
- HDDIRCDRQXPDLH-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-fluorophenoxy)ethoxy]phenyl]-n-[(2-fluoro-5-methoxyphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound COC1=CC=C(F)C(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC(F)=CC=3Cl)Cl)=CC=2)=C1 HDDIRCDRQXPDLH-UHFFFAOYSA-N 0.000 claims 1
- SBJHBHPXWCJVGB-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-fluorophenoxy)ethoxy]phenyl]-n-[(3,5-difluorophenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound FC1=CC(F)=CC(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC(F)=CC=3Cl)Cl)=CC=2)=C1 SBJHBHPXWCJVGB-UHFFFAOYSA-N 0.000 claims 1
- YEINQISTDIZAQY-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-fluorophenoxy)ethoxy]phenyl]-n-[(3,5-dimethoxyphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound COC1=CC(OC)=CC(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC(F)=CC=3Cl)Cl)=CC=2)=C1 YEINQISTDIZAQY-UHFFFAOYSA-N 0.000 claims 1
- GHNVYNWDJXRPAN-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-fluorophenoxy)ethoxy]phenyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound ClC1=CC(F)=CC(Cl)=C1OCCOC1=CC=C(C=2CCNCC=2C(=O)N(CC=2C=C(OC(F)(F)F)C=CC=2)C2CC2)C=C1 GHNVYNWDJXRPAN-UHFFFAOYSA-N 0.000 claims 1
- WHYZTWUXNYYKEF-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-n-[(2-fluoro-5-methoxyphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound COC1=CC=C(F)C(CN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(OCCOC=3C(=CC(C)=CC=3Cl)Cl)=CC=2)=C1 WHYZTWUXNYYKEF-UHFFFAOYSA-N 0.000 claims 1
- VRPGPAGCRYVLMT-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-n-[(3,4-dimethoxyphenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CN(C(=O)C=1CNCCC=1C=1C=CC(OCCOC=2C(=CC(C)=CC=2Cl)Cl)=CC=1)C1CC1 VRPGPAGCRYVLMT-UHFFFAOYSA-N 0.000 claims 1
- HVZUNLVNOSXEIJ-UHFFFAOYSA-N n-cyclopropyl-4-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-n-[(3,5-difluorophenyl)methyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound ClC1=CC(C)=CC(Cl)=C1OCCOC1=CC=C(C=2CCNCC=2C(=O)N(CC=2C=C(F)C=C(F)C=2)C2CC2)C=C1 HVZUNLVNOSXEIJ-UHFFFAOYSA-N 0.000 claims 1
- ABRBXBOXWBLKLD-UHFFFAOYSA-N n-cyclopropyl-n-(2-phenylethyl)-4-[4-[2-(2,3,5-trimethylphenoxy)ethyl]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC(C)=C(C)C(OCCC=2C=CC(=CC=2)C=2CCNCC=2C(=O)N(CCC=2C=CC=CC=2)C2CC2)=C1 ABRBXBOXWBLKLD-UHFFFAOYSA-N 0.000 claims 1
- ORCKZUQGCHBZBY-UHFFFAOYSA-N n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-4-[4-[2-(2,6-difluoro-3-methylphenoxy)ethoxy]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=C(F)C(OCCOC=2C=CC(=CC=2)C=2CCNCC=2C(=O)N(CC=2C(=C(Cl)C=CC=2)Cl)C2CC2)=C1F ORCKZUQGCHBZBY-UHFFFAOYSA-N 0.000 claims 1
- XKFWZYDNBSWSSD-UHFFFAOYSA-N n-cyclopropyl-n-[2-(2-methylphenyl)ethyl]-4-[4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=CC=C1CCN(C(=O)C=1CNCCC=1C=1C=CC(CCCOC=2C(=C(F)C=CC=2F)F)=CC=1)C1CC1 XKFWZYDNBSWSSD-UHFFFAOYSA-N 0.000 claims 1
- XBVPVGJVPQEDQE-UHFFFAOYSA-N n-cyclopropyl-n-[2-(3-methylphenoxy)ethyl]-4-[4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl]-1,2,3,6-tetrahydropyridine-5-carboxamide Chemical compound CC1=CC=CC(OCCN(C2CC2)C(=O)C=2CNCCC=2C=2C=CC(CCCOC=3C(=C(F)C=CC=3F)F)=CC=2)=C1 XBVPVGJVPQEDQE-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0207102 | 2002-06-27 | ||
| EPPCT/EP02/07102 | 2002-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005102002A true RU2005102002A (ru) | 2005-09-20 |
Family
ID=29797098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005102002/04A RU2005102002A (ru) | 2002-06-27 | 2003-04-29 | Новые производные тетрагидропиридина |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060009497A1 (enExample) |
| EP (1) | EP1519920A1 (enExample) |
| JP (1) | JP2005532371A (enExample) |
| CN (1) | CN1662498A (enExample) |
| AU (1) | AU2003229746A1 (enExample) |
| BR (1) | BR0312000A (enExample) |
| CA (1) | CA2490138A1 (enExample) |
| CL (1) | CL2003002043A1 (enExample) |
| IL (1) | IL165887A0 (enExample) |
| MX (1) | MXPA04012136A (enExample) |
| NO (1) | NO20050290L (enExample) |
| PL (1) | PL375214A1 (enExample) |
| RU (1) | RU2005102002A (enExample) |
| TW (1) | TW200514772A (enExample) |
| WO (1) | WO2004002957A1 (enExample) |
| ZA (1) | ZA200408423B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004234040A1 (en) * | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
| BRPI0409881A (pt) * | 2003-04-29 | 2006-05-23 | Actelion Pharmaceuticals Ltd | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
| EP1622685A1 (en) * | 2003-04-30 | 2006-02-08 | Actelion Pharmaceuticals Ltd. | 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors |
| KR20060015573A (ko) * | 2003-05-02 | 2006-02-17 | 액테리온 파마슈티칼 리미티드 | 신규한 디아자비시클로노넨 유도체 |
| WO2004105738A2 (en) * | 2003-05-30 | 2004-12-09 | Actelion Pharmaceuticals Ltd | Use of tetrahydropyridine derivatives |
| WO2005040120A1 (en) * | 2003-10-09 | 2005-05-06 | Actelion Pharmaceuticals Ltd | Tetrahydropyridine derivatives |
| JP2007508262A (ja) * | 2003-10-13 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規ジアザビシクロノネン誘導体およびその使用 |
| WO2005054243A1 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| EP1705176A4 (en) * | 2004-01-14 | 2009-06-03 | Takeda Pharmaceutical | CARBOXYLAMIDE DERIVATIVE AND ITS USE |
| NZ586285A (en) * | 2004-03-17 | 2011-12-22 | Novartis Ag | Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X) |
| ATE462703T1 (de) | 2004-08-25 | 2010-04-15 | Actelion Pharmaceuticals Ltd | Bicyclononen-derivate als renin-inhibitoren |
| GB0428526D0 (en) * | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0504850D0 (en) * | 2005-03-09 | 2005-04-13 | Novartis Ag | Organic compounds |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| BRPI0609890A2 (pt) * | 2005-05-27 | 2010-05-04 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| WO2007049224A1 (en) * | 2005-10-25 | 2007-05-03 | Actelion Pharmaceuticals Ltd | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives |
| RU2425032C2 (ru) | 2006-02-02 | 2011-07-27 | Актелион Фармасьютикалз Лтд | Вторичные амины в качестве ингибиторов ренина |
| BRPI0708487A2 (pt) * | 2006-03-03 | 2011-05-31 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica que o compreende e seu uso |
| CL2007000595A1 (es) * | 2006-03-08 | 2008-01-04 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. |
| EP1908471A1 (en) * | 2006-10-04 | 2008-04-09 | Speedel Experimenta AG | Tetrahydropyridines as renin inhibitors |
| US8343968B2 (en) | 2007-05-24 | 2013-01-01 | Merck Canada Inc. | Case of renin inhibitors |
| WO2009023964A1 (en) | 2007-08-20 | 2009-02-26 | Merck Frosst Canada Ltd. | Renin inhibitors |
| CA2722734C (en) | 2008-05-05 | 2013-11-05 | Merck Frosst Canada Ltd. | 3,4-substituted piperidine derivatives as renin inhibitors |
| CA2936749C (en) | 2010-06-11 | 2019-07-09 | Joshua R. Giguere | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| JP2013529595A (ja) | 2010-06-11 | 2013-07-22 | ローズ テクノロジーズ | 第３級アミンのｎ−脱アルキル化方法 |
| CN117865941B (zh) * | 2024-03-13 | 2024-06-28 | 上海方予健康医药科技有限公司 | 取代哌啶化合物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376666A (en) * | 1992-11-30 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl |
| KR100384979B1 (ko) * | 1995-09-07 | 2003-10-17 | 에프. 호프만-라 로슈 아게 | 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘 |
| US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
-
2003
- 2003-04-29 BR BR0312000-7A patent/BR0312000A/pt not_active IP Right Cessation
- 2003-04-29 RU RU2005102002/04A patent/RU2005102002A/ru not_active Application Discontinuation
- 2003-04-29 PL PL03375214A patent/PL375214A1/xx not_active Application Discontinuation
- 2003-04-29 EP EP03722566A patent/EP1519920A1/en not_active Withdrawn
- 2003-04-29 CN CN038138875A patent/CN1662498A/zh active Pending
- 2003-04-29 AU AU2003229746A patent/AU2003229746A1/en not_active Abandoned
- 2003-04-29 JP JP2004516551A patent/JP2005532371A/ja active Pending
- 2003-04-29 CA CA002490138A patent/CA2490138A1/en not_active Abandoned
- 2003-04-29 US US10/514,164 patent/US20060009497A1/en not_active Abandoned
- 2003-04-29 WO PCT/EP2003/004445 patent/WO2004002957A1/en not_active Ceased
- 2003-04-29 MX MXPA04012136A patent/MXPA04012136A/es unknown
- 2003-10-10 CL CL200302043A patent/CL2003002043A1/es unknown
- 2003-10-28 TW TW092129927A patent/TW200514772A/zh unknown
-
2004
- 2004-10-18 ZA ZA200408423A patent/ZA200408423B/xx unknown
- 2004-12-21 IL IL16588704A patent/IL165887A0/xx unknown
-
2005
- 2005-01-19 NO NO20050290A patent/NO20050290L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200514772A (en) | 2005-05-01 |
| MXPA04012136A (es) | 2005-04-19 |
| PL375214A1 (en) | 2005-11-28 |
| US20060009497A1 (en) | 2006-01-12 |
| CN1662498A (zh) | 2005-08-31 |
| WO2004002957A1 (en) | 2004-01-08 |
| IL165887A0 (en) | 2006-01-15 |
| CA2490138A1 (en) | 2004-01-08 |
| ZA200408423B (en) | 2005-10-11 |
| CL2003002043A1 (es) | 2005-01-28 |
| NO20050290L (no) | 2005-01-19 |
| AU2003229746A1 (en) | 2004-01-19 |
| BR0312000A (pt) | 2005-03-22 |
| JP2005532371A (ja) | 2005-10-27 |
| EP1519920A1 (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005102002A (ru) | Новые производные тетрагидропиридина | |
| JP2005532371A5 (enExample) | ||
| US20240293363A1 (en) | Methods and compositions for improving cognitive function | |
| RU2006133898A (ru) | Производные бензимидазола и его применение | |
| RU2001120016A (ru) | Ароматические гетероциклические соединения, обладающие активностью в отношении ВИЧ-интегразы | |
| RU2005137155A (ru) | Производные 9-азабицикло [3.3.1] нон-6-ена с гетероатомом на позиции 3 как ингибиторы ренина | |
| RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
| RU2358972C2 (ru) | Производные арилхиназолина, которые способствуют высвобождению паратиреоидного гормона | |
| RU2005139524A (ru) | Ингибиторы гфат | |
| KR0139626B1 (ko) | 강심제 | |
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| JP2006524686A5 (enExample) | ||
| RU2005137571A (ru) | Новые производные диазабициклононена | |
| RU2007126761A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ CRTh2 | |
| RU99113446A (ru) | Гуанидильные гетероциклические соединения, применяемые в качестве агонистов альфа-2 адренорецепторов | |
| RU2005137184A (ru) | Новые производные тропана | |
| RU2005136986A (ru) | Новые 3,4-дизамещенные производные 1,2,3,6-тетрагидропиридина | |
| EP3132803A2 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| CA2643005A1 (en) | Imidazole-5-carboxylic acid derivatives,the preparation method therefor and the uses thereof | |
| WO2008019106A1 (en) | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor | |
| EP0506545B1 (fr) | Utilisation de 4-amino-1-(2-pyridyl)pipéridines comme agonistes 5-HT3 pour le traitement et la prophylaxie des dysfonctionnements sérotoninergiques | |
| CA2099447A1 (en) | Angiotensin ii receptor antagonists for the treatment and prophylaxis of coronary heart disease | |
| RU2005100761A (ru) | Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов | |
| JP2018527316A5 (enExample) | ||
| CA2219455C (fr) | Utilisation de derives de pyrrolidine au traitement de l'alcoolisme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060704 |